Literature DB >> 20974340

The quality of life and health utility burden of recurrent respiratory papillomatosis in children.

Neil K Chadha1, Jennifer Allegro, Michelle Barton, Michael Hawkes, Hayley Harlock, Paolo Campisi.   

Abstract

OBJECTIVE: In this study we 1) measured the impact of juvenile-onset recurrent respiratory papillomatosis on health-related quality of life, voice-related quality of life, and family psychosocial well-being; and 2) compared these different measures, exploring their intercorrelation and their correlation with clinical disease severity. STUDY
DESIGN: Cross-sectional qualitative study.
SETTING: Tertiary academic pediatric hospital. SUBJECTS AND METHODS: Twenty consecutive children with active juvenile-onset recurrent respiratory papillomatosis (JoRRP) were included. Standardized interviews were performed on parents and children with the use of four validated tools: the Health Utilities Index version 3; the Pediatric Voice-Related Quality of Life survey; the Impact on Family Scale; and a visual analogue health preference measure. Clinical disease severity and demographic data also were collected.
RESULTS: Subjects (13 male, 7 female) had a median age of 9.2 years, median age of JoRRP onset of 3.8 years, and averaged four procedures per year of disease. Mean health utility was 0.76 (95% confidence interval 0.68-0.84) on a scale of 0 (death) to 1 (perfect health). Marked impact on voice-related quality of life and family psychosocial health also was identified. Health burden correlated poorly with existing methods of severity scoring.
CONCLUSION: This is the first study to use validated measures of health utility, voice-related quality of life, and psychosocial impact. This information has public health implications, providing essential parameters for accurate modeling studies and cost-utility analysis of future interventions, including different human papilloma virus vaccination strategies.
Copyright © 2010 American Academy of Otolaryngology–Head and Neck Surgery Foundation. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20974340     DOI: 10.1016/j.otohns.2010.08.005

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  8 in total

1.  Office-based Management of Recurrent Respiratory Papilloma.

Authors:  Kevin M Motz; Alexander T Hillel
Journal:  Curr Otorhinolaryngol Rep       Date:  2016-03-31

2.  Mapping the PedsQL™ onto the CHU9D: An Assessment of External Validity in a Large Community-Based Sample.

Authors:  Christine Mpundu-Kaambwa; Gang Chen; Elisabeth Huynh; Remo Russo; Julie Ratcliffe
Journal:  Pharmacoeconomics       Date:  2019-09       Impact factor: 4.981

3.  High recurrence rate in patients with juvenile-onset respiratory papillomatosis and its risk factors.

Authors:  Xiaoli Qu; Yang Xiao; Lijing Ma; Zijie Niu; Jun Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-04-20       Impact factor: 2.503

4.  A Novel In Vivo Model of Laryngeal Papillomavirus-Associated Disease Using Mus musculus Papillomavirus.

Authors:  Renee E King; Andrea Bilger; Josef Rademacher; Ella T Ward-Shaw; Rong Hu; Paul F Lambert; Susan L Thibeault
Journal:  Viruses       Date:  2022-05-08       Impact factor: 5.818

5.  Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.

Authors:  Mark Jit; Ruth Chapman; Owain Hughes; Yoon Hong Choi
Journal:  BMJ       Date:  2011-09-27

6.  Measuring Health Utilities in Children and Adolescents: A Systematic Review of the Literature.

Authors:  Dominic Thorrington; Ken Eames
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

7.  Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.

Authors:  Steven Simoens; Andre Bento-Abreu; Barbara Merckx; Sophie Joubert; Steve Vermeersch; Andrew Pavelyev; Stefan Varga; Edith Morais
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

Review 8.  Juvenile-Onset Recurrent Respiratory Papillomatosis Diagnosis and Management - A Developing Country Review.

Authors:  R Y Seedat
Journal:  Pediatric Health Med Ther       Date:  2020-02-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.